from Collective Evolution:
Infanrix Hexa (DTaP/IPV/Hib/HepB), made by Glaxosmithkline, is a 6- in- 1 vaccine which was released onto the global market in the year 2000, and since then across 97 countries around the world including Europe, Canada, Australia and New Zealand. It aims to protect against Diphtheria, Tetanus, Pertussis, Polio, Hib & Hepatitis B.
It was added to the UK vaccination schedule on 1st August 2017, with the sole purpose of introducing Hepatitis B into routine infant vaccinations. It is scheduled to be given at 8, 12 & 16 weeks of age and is to be administered alongside other recommended vaccines from the NHS Immunisation Schedule at age appropriate appointments.(ref 1)
Hepatitis B has a very low incidence rate in the UK (0.3 – 0.4%). It is spread via blood-to-blood contact through percutaneous exposure (e.g. sharing of needles and other equipment by people who inject drugs or through contaminated ‘needle stick’ injuries), sexual intercourse with an infected person and perinatal transmission from a mother to child (0.05 to 0.08%).
Apart from seropositive mothers, it’s highly unlikely an infant will contract Hepatitis B through these means. (ref 2)
An Italian court Judge, Nicola Di Leo, made GlaxoSmithKline’s confidential periodic safety update reports (PSURs), from 2009 to 2011, available to the public. A number of SIDS cases have been observed in this document (ref 3).
The observed deaths were less than what was expected.
However, among the infants, there was a clustering of deaths immediately following vaccination, with 42 deaths taking place in the first three days after vaccination, and only 8 in the next 3 days.
Among those below one year of age, 54 deaths (93%) occurred in the first 10 days, and 4 (7%) in the next 10 days. Had the deaths been “coincidental SIDS deaths,” this disparity in the number of deaths in the two-time periods would not have been observed.
SIDS deaths would have been spread uniformly over the 20-day period. The fact that the rate of death decreases rapidly with the passage of time following immunisation suggests that the deaths could be related to vaccination (ref 4). Investigations are still ongoing. (ref 5)
The package insert for Infanrix Hexa states that ‘’Increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed with concomitant administration of Infanrix hexa and Prevenar 13 (see section 4.8). (ref 6) Infants are scheduled to receive this combination at 8 and 12 weeks.
People Who Are Hypersensitive To Some Of The Ingredients Must Not Have This Vaccine
Infanrix Hexa should not be administered to subjects with known hypersensitivity to the active substances or to any of the excipients or residues – which include Pertussis Toxoid, Tetanus Toxoid, Diphtheria toxoid, Aluminium Phosphate, Aluminium Hydroxide, formaldehyde, neomycin, polymyxin, VERO cells (monkey kidney cells), Latex or Yeast. Please read the package insert carefully before consenting (ref 6).
For a more detailed list of reported adverse reactions please visit www.vigiaccess.org medicines database, type in ‘’Infanrix Hexa’’ into the search bar, then view each drop-down box individually.